Pluto Biosciences, Inc

GSE142560 (human): Gene expression profile of HSPC with cell-intrinsic innate immune signaling activation after LPS treatment

Bulk RNA sequencing

The underlying mechanisms responsible for the competitive advantage of MDS HSPC in an inflammatory milieu remains poorly defined. Here, we show that MDS HPSC are protected from low-grade chronic inflammation, and that the adaptive response of these cells to the inflammatory milieu via the non-canonical NF-B pathway contributes to sustained myeloid expansion and a competitive advantage. These findings uncover the mechanistic basis for the clonal dominance of functionally impaired MDS HSPC and reveal the therapeutic potential of interfering with non-canonical NF-B signaling. SOURCE: Kwangmin Choi Cincinnati Children's Hospital Medical Center

View this experiment on Pluto Biosciences, Inc